Comparison of Systemic and Mucosal Immunization with Helper-Dependent Adenoviruses for Vaccination against Mucosal Challenge with SHIV

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Weaver, Eric A ^a   Nehete, Pramod N ^c   Nehete, Bharti P ^c   Yang, Guojun ^c   Buchl, Stephanie J ^c   Hanley, Patrick W ^c   Palmer, Donna ^d   Montefiori, David C ^e   Ferrari, Guido ^e   Ng, Philip ^d   Sastry, K Jagannadha ^c   Barry, Michael A ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CYTOTOXIC ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY;

ADENOVIRUS; ADENOVIRUS 1; ADENOVIRUS 2; ADENOVIRUS 5; ADENOVIRUS 6; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; MUCOSAL IMMUNIZATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RHESUS MONKEY; SEXUALLY TRANSMITTED DISEASE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SYSTEMIC IMMUNIZATION; T LYMPHOCYTE; VACCINATION; VIRUS ENVELOPE;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; GENETIC VECTORS; HELPER VIRUSES; IMMUNITY; IMMUNITY, MUCOSAL; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; MUCOUS MEMBRANE; PERFORIN; RECEPTORS, CCR5; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VAGINA; VIRAL TROPISM;

ADENOVIRIDAE; ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84879778086     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067574     Document Type: Article

References (37)

1. Campos SK, Barry MA, (2007) Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 7: 189-204.
2. Lubeck MD, Natuk R, Myagkikh M, Kalyan N, Aldrich K, et al. (1997) Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med 3: 651-658.
3. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, et al. (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
4. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, et al. (2003) Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77: 6305-6313.
5. Pinto AR, Fitzgerald JC, Giles-Davis W, Gao GP, Wilson JM, et al. (2003) Induction of CD8(+) T Cells to an HIV-1 Antigen through a Prime Boost Regimen with Heterologous E1-Deleted Adenoviral Vaccine Carriers. J Immunol 171: 6774-6779.
6. Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gomez-Roman VR, et al. (2004) Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 78: 2212-2221.
7. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, et al. (2004) Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172: 6290-6297.
8. Benlahrech A, Harris J, Meiser A, Papagatsias T, Hornig J, et al. (2009) Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci U S A 106: 19940-19945.
9. Someya K, Xin KQ, Ami Y, Izumi Y, Mizuguchi H, et al. (2007) Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys. Virology.
10. Weaver EA, Nehete PN, Buchl SS, Palmer D, Montefiori D, et al. (2009) Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines. Viruses 1: 920-938.
11. Santra S, Sun Y, Korioth-Schmitz B, Fitzgerald J, Charbonneau C, et al. (2009) Heterologous prime/boost immunizations of rhesus monkeys using chimpanzee adenovirus vectors. Vaccine 27: 5837-5845.
12. Weaver EA, Nehete PN, Buchl SS, Senac JS, Palmer D, et al. (2009) Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS ONE 4: e5059.
13. Chen HH, Mack LM, Kelly R, Ontell M, Kochanek S, et al. (1997) Persistence in muscle of an adenoviral vector that lacks all viral genes. Proceedings of the National Academy of Sciences of the United States of America 94: 1645-1650.
14. Kim IH, Jozkowicz A, Piedra PA, Oka K, Chan L, (2001) Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A 98: 13282-13287.
15. Morral N, O'Neal W, Rice K, Leland M, Kaplan J, et al. (1999) Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons. Proc Natl Acad Sci U S A 96: 12816-12821.
16. Morral N, Parks RJ, Zhou H, Langston C, Schiedner G, et al. (1998) High doses of a helper-dependent adenoviral vector yield supraphysiological levels of a1-antitrypsin with neglible toxicity. Hum Gene Ther 9: 2709-2716.
17. Lehner T, Anton PA, (2002) Mucosal immunity and vaccination against HIV. Aids 16Suppl 4: S125-132.
18. Hsu M, Buckner C, Harouse J, Gettie A, Blanchard J, et al. (2003) Antigenic variations in the CD4 induced sites of the CCR5-tropic, pathogenic SHIVsf162p3 gp120 variants. J Med Primatol 32: 211-217.
19. Balfe P, Shapiro S, Hsu M, Buckner C, Harouse JM, et al. (2004) Expansion of quasispecies diversity but no evidence for adaptive evolution of SHIV during rapid serial transfers among seronegative macaques. Virology 318: 267-279.
20. Reyes RA, Canfield DR, Esser U, Adamson LA, Brown CR, et al. (2004) Induction of simian AIDS in infant rhesus macaques infected with CCR5- or CXCR4-utilizing simian-human immunodeficiency viruses is associated with distinct lesions of the thymus. J Virol 78: 2121-2130.
21. Hsu M, Harouse JM, Gettie A, Buckner C, Blanchard J, et al. (2003) Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120. J Virol 77: 989-998.
22. Harouse JM, Gettie A, Eshetu T, Tan RC, Bohm R, et al. (2001) Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3). J Virol 75: 1990-1995.
23. Weaver EA, Nehete PN, Nehete BP, Buchl SJ, Palmer D, et al. (2009) Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines. Viruses 1: 920.
24. Mercier GT, Nehete PN, Passeri MF, Nehete BN, Weaver EA, et al. (2007) Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 25: 8687-8701.
25. Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, et al. (2005) Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 79: 9694-9701.
26. McCoy K, Tatsis N, Korioth-Schmitz B, Lasaro MO, Hensley SE, et al. (2007) Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol 81: 6594-6604.
27. Frahm N, Decamp AC, Friedrich DP, Carter DK, Defawe OD, et al. (2012) Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 122: 359-367.
28. Cohen J (2011) AIDS research. Novel antibody response may explain HIV vaccine success. Science 333.
29. Mok H, Palmer DJ, Ng P, Barry MA, (2005) Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 11: 66-79.
30. Palmer D, Ng P, (2003) Improved System for Helper-dependent adenoviral vector production. Molecular Therapy 8: 846-852.
31. Parks R, Evelegh C, Graham F, (1999) Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration. Gene Ther 6: 1565-1573.
32. Mitchell MF, Hamada K, Sastry KJ, Sarkar A, Tortolero-Luna G, et al. (1996) Transgene expression in the rhesus cervix mediated by an adenovirus expressing beta-galactosidase. Am J Obstet Gynecol 174: 1094-1101.
33. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.
34. Montefiori DC (2005) Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol Chapter 12: Unit 12 11.
35. Pollara J, Hart L, Brewer F, Pickeral J, Packard BZ, et al. (2011) High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 79: 603-612.
36. Nehete PN, Gambhira R, Nehete BP, Sastry KJ, (2003) Dendritic cells enhance detection of antigen-specific cellular immune responses by lymphocytes from rhesus macaques immunized with an HIV envelope peptide cocktail vaccine. J Med Primatol 32: 67-73.
37. He H, Nehete PN, Nehete B, Wieder E, Yang G, et al. (2011) Functional impairment of central memory CD4 T cells is a potential early prognostic marker for changing viral load in SHIV-infected rhesus macaques. PLoS One 6: e19607.